Compare SPAI & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPAI | ENTX |
|---|---|---|
| Founded | 2021 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.0M | 74.7M |
| IPO Year | 2024 | 2018 |
| Metric | SPAI | ENTX |
|---|---|---|
| Price | $6.10 | $1.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $10.00 | $10.00 |
| AVG Volume (30 Days) | ★ 321.4K | 305.3K |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,266,756.00 | $124,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $629.15 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 25.25 |
| 52 Week Low | $1.47 | $1.45 |
| 52 Week High | $9.16 | $3.22 |
| Indicator | SPAI | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 63.35 | 40.18 |
| Support Level | $5.73 | $1.55 |
| Resistance Level | $5.99 | $1.72 |
| Average True Range (ATR) | 0.66 | 0.16 |
| MACD | 0.14 | 0.01 |
| Stochastic Oscillator | 79.08 | 24.19 |
Safe Pro Group Inc operates to acquire security and protection products. Its emphasis is on the development of a cloud-based ecosystem for analyzing drone imagery and data utilizing proprietary artificial intelligence (AI), machine learning, deep learning, and applied computer vision software for hyper-scalable processing, analysis, and reporting. The company operated in three reportable business segments which consisted of: the business of Safe-Pro USA, the business of Airborne Response, and the business of Safe Pro AI. Key revenue is generated from Airborne Response.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.